Schoellnast Helmut, Tillich Manfred, Deutschmann Hannes A, Deutschmann Michael J, Fritz Gerald A, Stessel Uwe, Schaffler Gottfried J, Uggowitzer Martin M
Department of Radiology, University Hospital, Graz, Austria.
J Comput Assist Tomogr. 2003 Nov-Dec;27(6):847-53. doi: 10.1097/00004728-200311000-00002.
To evaluate the potential of a saline solution flush after the contrast material bolus in abdominal multidetector row CT (MDCT) in contrast material dose and cost reduction.
Abdominal MDCT was performed in 78 patients who were assigned randomly to 2 groups receiving 120 mL nonionic contrast material (300 mgI/mL) alone or 100 mL of the same contrast material pushed with 40 mL of saline solution. Mean attenuation values for both groups were measured in the liver, the spleen, the pancreas, the portal vein, the inferior vena cava, and the abdominal aorta. Cost analyses were performed for both groups.
There was no significant difference in parenchymal and vascular enhancement between both groups. The difference of the enhancement was 2 HU for the liver (P = 0.11), 2 HU for the spleen (P = 0.44), 3 HU for the pancreas (P = 0.38), 9 HU for the portal vein (P = 0.11), 3 HU for the inferior vena cava (P = 0.55), and 10 HU for the aorta (P = 0.06). Taking the costs of contrast material, saline solution, and disposal material into account, 7.30 dollars was saved by the patient using a saline solution flush.
Using a saline flush after the contrast material bolus in abdominal MDCT allows an iodine dose reduction of approximately 6 g, or 17%, without impairing mean parenchymal and vascular enhancement and a cost reduction of 7.30 dollars per patient.
评估在腹部多排螺旋CT（MDCT）中造影剂团注后用生理盐水冲洗在降低造影剂剂量和成本方面的潜力。
对78例患者进行腹部MDCT检查，这些患者被随机分为两组，一组单独接受120 mL非离子型造影剂（300 mgI/mL），另一组接受100 mL相同造影剂并推注40 mL生理盐水。测量两组在肝脏、脾脏、胰腺、门静脉、下腔静脉和腹主动脉的平均衰减值。对两组进行成本分析。
两组之间实质和血管强化无显著差异。肝脏强化差异为2 HU（P = 0.11），脾脏为2 HU（P = 0.44），胰腺为3 HU（P = 0.38），门静脉为9 HU（P = 0.11），下腔静脉为3 HU（P = 0.55），主动脉为10 HU（P = 0.06）。考虑造影剂、生理盐水和处置材料的成本，使用生理盐水冲洗的患者每人节省7.30美元。
在腹部MDCT造影剂团注后使用生理盐水冲洗可使碘剂量减少约6 g，即17%，而不影响实质和血管的平均强化，且每位患者成本降低7.30美元。
